Buenos Aires, May 20 (NA) — Argentina is one of the twelve countries in the world that produces vaccines and the local biotechnology industry is a high value-added sector that generates exports of more than 216 million dollars annually, highlighted the secretary of Industry, José Ignacio de Mendiguren.
It was during a meeting at the plant of the firm mAbxience, a leader in the production of monoclonal antibodies that plans to triple its production capacity by March 2024.
Mendiguren held a working meeting with biotechnology companies and startups enrolled in the Argentine Chamber of Biotechnology (CAB).
The meeting was held at the mAbxience plant, a leading company in the production of monoclonal antibodies that plans to triple its production capacity by March 2024, reported Industry.
“This industry has a very important objective for the country because it positions Argentina in the world. There are not many countries that produce biotechnology, and these companies brought together in a chamber, together, realize our potential as a country, raises pride and self-esteem to Argentines,” said Mendiguren.
“We are very clear that Argentina is going ahead producing, generating a productive matrix different from the traditional one and you are a key sector for this structural change,” he said.
For his part, the vice president of the CAB, Sebastián Bagó, pointed out that “currently the Chamber has 35 mature companies, 92 startups and 3 accelerators. These 35 companies represent 726 million dollars in turnover, 216 million dollars in exports, plus of 18,000 direct jobs, more than 650 people doing research and development and investing 4.6% of their turnover in R&D, which is more than triple the industrial average”.
“We are an engine of economic growth and for our industry it is important to have promotion and support instruments, which is why this relationship with the Ministry of Industry is very relevant so that we can exchange opinions and information,” he said.
Mendiguren also toured the plant of the biotechnological company mAbxience, which is dedicated to the development, manufacture and commercialization of biotechnological products for human medicine.
Currently, it is in the middle of the expansion stage with the aim of tripling its productive capacity by March 2024.
It has been operating in Argentina since 2009, with two plants in the province of Buenos Aires. One of them in the town of Garín, which was inaugurated in February 2020 for the specific preparation of monoclonal antibodies that act as human antibodies in the immune system, a specific biological alternative for the treatment of certain types of cancer and autoimmune diseases.
Representatives of CAB member companies were also present at the meeting, such as Gador, Wiener Lab, Sinergium Biotech, Amega Biotech, Bioprofarma Bagó, Argenomics, Terragene, Kheiron, Porta, Diagramma, INSUD, Bioceres, Biogénesis Bagó, Richmond, Casasco, Denver Farma, SA San Miguel, Elea, Inbio Highway, Biosidus, Grupo Harmony and Craveri, together with the executive coordinator of the CAB and members of the company mAbxience.
JC/PT
http://www.facebook.com/AgenciaNA
NA 05-20-23 12:58:27
Source: Ambito
